Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Divi’s Laboratories Limited ( (IN:DIVISLAB) ) has shared an announcement.
Divi’s Laboratories Limited has announced that it will close its trading window for designated persons, their immediate relatives, and insiders from 1 January 2026 until 48 hours after the company announces its unaudited financial results for the quarter and nine-month period ended 31 December 2025. The move is in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s internal code of conduct, reinforcing its governance standards and compliance framework ahead of the upcoming financial disclosure, with the exact board meeting date for approving these results to be communicated later.
More about Divi’s Laboratories Limited
Divi’s Laboratories Limited is an Indian pharmaceutical company primarily engaged in manufacturing active pharmaceutical ingredients (APIs) and intermediates, catering to global generic and custom synthesis markets.
Average Trading Volume: 9,102
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1696.2B INR
See more data about DIVISLAB stock on TipRanks’ Stock Analysis page.